Drugs / NouvNeu001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07550374 | May 2026 → Apr 2028 expected | Parkinson disease | iRegene Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06167681 | Jan 2024 → Dec 2025 overdue | Parkinson disease | iRegene Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NouvNeu001 | “This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells...” NCT06167681 ↗ |
| Known as | Human Dopaminergic Progenitor Cells | “This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells...” NCT06167681 ↗ |
| Modality | Cell therapy | “Human Dopaminergic Progenitor Cells” NCT06167681 ↗ |
| Route | Other | “The NouvNeu001 will be transplanted into bilateral putamen/striatum using stereotactic neurosurgery.” NCT06167681 ↗ |